5-(2-methoxyethoxy)-3-(3-phenoxyphenyl)-1,3,4-oxadiazol-2(3H)-one

ID: ALA4793132

Chembl Id: CHEMBL4793132

PubChem CID: 162671503

Max Phase: Preclinical

Molecular Formula: C17H16N2O5

Molecular Weight: 328.32

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  COCCOc1nn(-c2cccc(Oc3ccccc3)c2)c(=O)o1

Standard InChI:  InChI=1S/C17H16N2O5/c1-21-10-11-22-16-18-19(17(20)24-16)13-6-5-9-15(12-13)23-14-7-3-2-4-8-14/h2-9,12H,10-11H2,1H3

Standard InChI Key:  PVSASTNOGBPBCG-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4793132

    ---

Associated Targets(Human)

PNLIP Tclin Pancreatic lipase (198 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

LIPF Gastric triacylglycerol lipase (84 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PNLIPRP2 Pancreatic lipase-related protein 2 (70 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PNLIP Pancreatic triacylglycerol lipase (476 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 328.32Molecular Weight (Monoisotopic): 328.1059AlogP: 2.64#Rotatable Bonds: 7
Polar Surface Area: 75.72Molecular Species: NEUTRALHBA: 7HBD:
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: 3.73CX LogD: 3.73
Aromatic Rings: 3Heavy Atoms: 24QED Weighted: 0.62Np Likeness Score: -1.20

References

1. Point V,Bénarouche A,Zarrillo J,Guy A,Magnez R,Fonseca L,Raux B,Leclaire J,Buono G,Fotiadu F,Durand T,Carrière F,Vaysse C,Couëdelo L,Cavalier JF.  (2016)  Slowing down fat digestion and absorption by an oxadiazolone inhibitor targeting selectively gastric lipolysis.,  123  [PMID:27543878] [10.1016/j.ejmech.2016.08.009]
2. Cavalier JF, Spilling CD, Durand T, Camoin L, Canaan S..  (2021)  Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery.,  209  [PMID:33071055] [10.1016/j.ejmech.2020.112908]

Source